Guardant Health's gross profit for the
three
months ended in Mar. 2022 was $64.1 Mil. Guardant Health's gross profit for the trailing twelve months (TTM) ended in Mar. 2022 was $264.9 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Guardant Health's gross profit for the
three
months ended in Mar. 2022 was $64.1 Mil. Guardant Health's Revenue for the
three
months ended in Mar. 2022 was $96.1 Mil. Therefore, Guardant Health's Gross Margin % for the quarter that ended in Mar. 2022 was 66.72%.
Guardant Health had a gross margin of 66.72% for the quarter that ended in Mar. 2022 => Durable competitive advantage
During the past 6 years, the highestGross Margin % of Guardant Health was 67.74%. The lowest was 12.38%. And the median was 59.67%.
Guardant Health Gross Profit Historical Data
The historical data trend for Guardant Health's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Guardant Health Annual Data
Trend
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Gross Profit
18.22
47.43
143.66
194.20
250.74
Guardant Health Quarterly Data
Dec16
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Gross Profit
49.92
62.17
63.96
74.69
64.12
Competitive Comparison
For the Diagnostics & Research subindustry, Guardant Health's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health Gross Profit Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Gross Profit distribution charts can be found below:
* The bar in red indicates where Guardant Health's Gross Profit falls into.
Guardant Health Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Guardant Health's Gross Profit for the fiscal year that ended in Dec. 2021 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $264.9 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
Guardant Health's Gross Margin % for the quarter that ended in Mar. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Guardant Health (NAS:GH) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Guardant Health had a gross margin of 66.72% for the quarter that ended in Mar. 2022 => Durable competitive advantage
Guardant Health Gross Profit Related Terms
Thank you for viewing the detailed overview of Guardant Health's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.87(2.48%) Volume: 1,362,712 1:47PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:GH has been successfully added to your 
